A Phase 2 interventional study of Sucrose and Pacifier in Infant, Premature, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 3 Days to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-08.
Sponsored by Norwegian University of Science and Technology · Phase 2 and Interventional
Does sucrose or pacifier influence pain in premature babies when a nasogastric tube is inserted?
A total of 24 premature babies are randomised to receive either placebo (sterile water), 30 % sucrose, or pacifier in a complete factorial, cross-over design. Pain is rated on the PIPP scale by observers blinded to the procedure other than use of pacifier.
2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.
This study's enrollment of 24 is below the median of 84 across 1,689 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Norwegian University of Science and Technology is the lead sponsor of 487 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
no fluid, no pacifier
water, no pacifier
Other: sterile water
Sucrose, no pacifier
Drug: Sucrose
No fluid, pacifier
Device: Pacifier
water, pacifier
Device: Pacifier
sucrose, pacifier
Drug: Sucrose · Device: Pacifier
30 % sucrose
Pain measured on PIPP (Premature Infant Pain Profile) scale
Time frame: 4 week to complete
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology